Neuronetics (STIM) Projected to Post Earnings on Tuesday

Neuronetics (NASDAQ:STIM) will likely be issuing its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $37.8460 million for the quarter. Neuronetics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 8:30 AM ET.

Neuronetics (NASDAQ:STIM) last released its earnings results on Tuesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.07). The firm had revenue of $38.11 million during the quarter, compared to analyst estimates of $36.80 million. Neuronetics had a negative net margin of 43.47% and a negative return on equity of 156.36%. On average, analysts expect Neuronetics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Neuronetics Stock Performance

NASDAQ STIM opened at $2.65 on Friday. The company has a market cap of $175.23 million, a P/E ratio of -2.35 and a beta of 1.17. The company has a debt-to-equity ratio of 1.76, a current ratio of 2.02 and a quick ratio of 1.84. The stock has a 50-day moving average of $2.99 and a two-hundred day moving average of $3.60. Neuronetics has a 1-year low of $0.52 and a 1-year high of $5.92.

Hedge Funds Weigh In On Neuronetics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new position in Neuronetics in the second quarter valued at approximately $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Neuronetics in the second quarter valued at approximately $69,000. Invesco Ltd. purchased a new stake in Neuronetics in the second quarter valued at approximately $100,000. New York State Common Retirement Fund purchased a new stake in Neuronetics in the second quarter valued at approximately $103,000. Finally, Jump Financial LLC purchased a new stake in Neuronetics in the second quarter valued at approximately $133,000. 53.59% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

STIM has been the subject of a number of analyst reports. Canaccord Genuity Group lowered their price objective on Neuronetics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Neuronetics in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $7.00.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.